Securing robust and relevant IP is critical to success in the pharmaceutical and biotechnology industry. When approaching any investment decision, pharmaceutical companies will have IP strategy at the forefront of their minds.
In this webinar, we will provide behind-the-scenes insights into how large pharmaceutical companies think about IP when evaluating new opportunities, negotiating deals and funding life-cycle management of on-market therapeutics.
Topics covered:
- How large pharmaceutical companies use IP in financial forecasting to model return of investment for biotech and pharmaceutical products.
- How pharmaceutical companies approach life cycle management through strategic IP filings at every stage of a products development.
- How to leverage your IP in deal making and negotiations with large pharmaceutical companies.
- Understanding the difference between the IP strategy for small molecules, biologics and advanced therapies.
Who should attend:
- Investors, business leaders and business development professionals in the pharma and biotech industry.
- Tech transfer professionals working in the pharma and biotech industry.
- In-house IP counsel at biotech companies.
- Anyone interested in commercialisation strategy for pharma and biotech innovation.
Speakers: Rose Hughes and Steven Gurney
